# A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants

> **NCT03080987** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-64179375 0.3 mg/kg
- **DRUG:** JNJ-64179375 1.0 mg/kg
- **DRUG:** JNJ-64179375 2.5 mg/kg
- **OTHER:** Placebo
- **DRUG:** JNJ-64179375 (Dose to be Determined)

## Key facts

- **NCT ID:** NCT03080987
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-27
- **Primary completion:** 2018-06-25
- **Final completion:** 2018-06-25
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03080987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03080987, "A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03080987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*